From: DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes
 | Total N | Events N | Model 1 | Model 2 | ||
---|---|---|---|---|---|---|
CVD | Â | Â | Â | Â | Â | Â |
 CVD events from DNAm measurement to EDIC year 20 | 496 | 58 | HR (95% CI) | p | HR (95% CI) | p |
  Pan-tissue |  |  | 1.03 (0.96–1.10) | 0.433 | 1.03 (0.96–1.11) | 0.371 |
  Skin & Blood |  |  | 1.06 (0.97–1.16) | 0.207 | 1.07 (0.97–1.18) | 0.166 |
  PhenoAge |  |  | 1.05 (0.99–1.10) | 0.086 | 1.05 (1.00–1.11) | 0.061 |
  GrimAge |  |  | 1.04 (0.99–1.10) | 0.163 | 1.04 (0.99–1.10) | 0.085 |
Nephropathy and renal function | Â | Â | Â | Â | Â | Â |
 Repeated eGFR from EDIC year 0 to 18 (ml/min/1.73 m2) | 498 | NA | Beta (SE) | p | Beta (SE) | p |
  Pan-tissue |  |  | − 0.17 (0.10) | 0.075 | − 0.18 (0.10) | 0.063 |
  Skin & Blood |  |  | − 0.20 (0.13) | 0.119 | − 0.23 (0.13) | 0.084 |
  PhenoAge |  |  | − 0.13 (0.08) | 0.099 | − 0.14 (0.08) | 0.068 |
  GrimAge |  |  | 0.05 (0.09) | 0.531 | 0.03 (0.09) | 0.736 |
 Sustained eGFR <60 ml/min/1.73 m2 during EDIC year 0-18 | 498 | 23 | HR (95% CI) | p | HR (95% CI) | p |
  Pan-tissue |  |  | 1.11 (0.99–1.26) | 0.077 | 1.12 (0.99–1.27) | 0.075 |
  Skin & Blood |  |  | 1.08 (0.94–1.23) | 0.287 | 1.07 (0.94–1.23) | 0.318 |
  PhenoAge |  |  | 1.06 (0.98–1.15) | 0.160 | 1.06 (0.97–1.14) | 0.199 |
  GrimAge |  |  | 1.04 (0.96–1.13) | 0.315 | 1.04 (0.95–1.13) | 0.432 |
 Repeated AER from EDIC year 0 to 18 (mg/24 h loge transformed) | 499 | NA | Beta (SE) | p | Beta (SE) | p |
  Pan-tissue |  |  | 0.011 (0.010) | 0.273 | 0.011 (0.011) | 0.282 |
  Skin & Blood |  |  | 0.021 (0.014) | 0.146 | 0.021 (0.014) | 0.138 |
  PhenoAge |  |  | 0.023 (0.008) | 6.78E−3 | 0.024 (0.009) | 4.83E−3 |
  GrimAge |  |  | 0.029 (0.009) | 2.13E−3 | 0.032 (0.009) | 7.23E−4 |
 AER ≥ 300 mg/24 h during EDIC year 0–18 | 484 | 29 | HR (95% CI) | p | HR (95% CI) | p |
  Pan-tissue |  |  | 1.04 (0.94–1.15) | 0.465 | 1.01 (0.91–1.12) | 0.846 |
  Skin & Blood |  |  | 1.05 (0.92–1.19) | 0.515 | 1.08 (0.94–1.24) | 0.292 |
  PhenoAge |  |  | 1.05 (0.97–1.12) | 0.211 | 1.04 (0.97–1.12) | 0.277 |
  GrimAge |  |  | 1.06 (0.98–1.14) | 0.152 | 1.04 (0.96–1.13) | 0.309 |
Retinopathy | Â | Â | Â | Â | Â | Â |
 SNPDR during EDIC year 0–18 | 473 | 92 | HR (95% CI) | p | HR (95% CI) | p |
  Pan-tissue |  |  | 1.02 (0.97–1.08) | 0.396 | 1.01 (0.95–1.07) | 0.765 |
  Skin & Blood |  |  | 1.06 (0.98–1.14) | 0.136 | 1.04 (0.96–1.13) | 0.343 |
  PhenoAge |  |  | 1.04 (0.99–1.08) | 0.111 | 1.03 (0.98–1.07) | 0.287 |
  GrimAge |  |  | 1.04 (0.99–1.08) | 0.135 | 1.00 (0.95–1.05) | 0.892 |
 PDR during EDIC year 0–18 | 482 | 96 | HR (95% CI) | p | HR (95% CI) | p |
  Pan-tissue |  |  | 1.01 (0.96–1.07) | 0.584 | 0.99 (0.94–1.05) | 0.790 |
  Skin & Blood |  |  | 1.05 (0.98–1.14) | 0.180 | 1.03 (0.95–1.12) | 0.497 |
  PhenoAge |  |  | 1.03 (0.99–1.08) | 0.131 | 1.02 (0.98–1.07) | 0.400 |
  GrimAge |  |  | 1.03 (0.98–1.07) | 0.256 | 0.99 (0.94–1.04) | 0.698 |
 CSME during EDIC year 0–18 | 464 | 108 | HR (95% CI) | p | HR (95% CI) | p |
  Pan-tissue |  |  | 1.04 (0.99–1.09) | 0.176 | 1.04 (0.98–1.09) | 0.179 |
  Skin & Blood |  |  | 1.00 (0.94–1.08) | 0.935 | 0.99 (0.92–1.07) | 0.827 |
  PhenoAge |  |  | 1.04 (1.00–1.08) | 0.091 | 1.01 (0.97–1.06) | 0.517 |
  GrimAge |  |  | 1.02 (0.97–1.06) | 0.428 | 1.00 (0.95–1.04) | 0.843 |
Neuropathy | Â | Â | Â | Â | Â | Â |
 DPN at EDIC year 13–15 | 431 | 109 | OR (95% CI) | p | OR (95% CI) | p |
  Pan-tissue |  |  | 1.02 (0.96–1.08) | 0.562 | 1.02 (0.96–1.09) | 0.466 |
  Skin & Blood |  |  | 0.96 (0.88–1.05) | 0.345 | 0.96 (0.88–1.05) | 0.352 |
  PhenoAge |  |  | 1.02 (0.98–1.07) | 0.356 | 1.02 (0.97–1.07) | 0.448 |
  GrimAge |  |  | 1.07 (1.02–1.12) | 9.24E−3 | 1.07 (1.01–1.12) | 2.17E−2 |
 CAN at EDIC year 13–18 | 446 | 176 | OR (95% CI) | p | OR (95% CI) | p |
  Pan-tissue |  |  | 1.01 (0.96–1.07) | 0.635 | 1.02 (0.97–1.07) | 0.526 |
  Skin & Blood |  |  | 0.99 (0.92–1.06) | 0.758 | 0.99 (0.92–1.07) | 0.844 |
  PhenoAge |  |  | 1.01 (0.97–1.05) | 0.689 | 1.00 (0.96–1.05) | 0.971 |
  GrimAge |  |  | 1.06 (1.01–1.11) | 1.07E−2 | 1.06 (1.01–1.11) | 2.39E−2 |